{"id":"mer4101","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T06:12:55.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T09:17:08.816110+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT01623232","phase":"PHASE1, PHASE2","title":"MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2012-10","conditions":"Influenza Vaccines, Aged","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inactivated Influenza Vaccine with MAS-1 Adjuvant"],"phase":"phase_1","status":"active","brandName":"MER4101","genericName":"MER4101","companyName":"Nova Immunotherapeutics Limited","companyId":"nova-immunotherapeutics-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T09:17:08.816110+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}